BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM ...

Brukinsa shows a more favorable safety profile than Imbruvica, with fewer severe side effects, especially neutropenia. Brukinsa may be preferable for patients at higher infection risk or requiring ...

Oyler may not be exaggerating. In a heated competition among BTK inhibitor treatments for blood cancer, BeiGene’s third-to-market Brukinsa has for the first time surpassed AstraZeneca’s ...

"With this final PFS analysis, Brukinsa has achieved superior progression free survival, as well as superiority in overall response rate versus ibrutinib," said BeiGene's chief medical officer for ...

We raise our fair value estimate for no-moat BeiGene to HKD 149 per share from HKD 132, based on better-than-expected Brukinsa sales in the last quarter and a faster ramp-up going forward.

Oyler, Co-Founder, Chairman, and CEO at BeiGene. “BRUKINSA is now the unequivocal leader in new CLL patient starts in the U.S., holds the broadest label of any BTK inhibitor and serves as the ...